Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067 by Figueroa, Dominique B. et al.
RESEARCH ARTICLE
Discovery of genetic variants of the kinases
that activate tenofovir among individuals in
the United States, Thailand, and South Africa:
HPTN067
Dominique B. Figueroa1☯, Joseph Tillotson2☯, Maoji Li3, Estelle Piwowar-Manning4, Craig
W. Hendrix2, Timothy H. Holtz5, Kevin Bokoch6, Linda-Gail Bekker7, Frits van Griensven8,
Sharon Mannheimer9, James P. Hughes10, Robert M. Grant11, Namandje´ N. Bumpus2*
1 Department of Pharmacology & Molecular Sciences, Johns Hopkins University School of Medicine,
Baltimore, MD, United States of America, 2 Department of Medicine (Division of Clinical Pharmacology),
Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, 3 Vaccine and
Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of
America, 4 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United
States of America, 5 HIV/STD Research Program, Thailand Ministry of Public Health–U.S. Centers for
Disease Control and Prevention Collaboration, Nonthaburi, Thailand. Division of HIV/AIDS Prevention,
U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 6 FHI 360,
Research Triangle Park, NC, United States of America, 7 The Desmond Tutu HIV Centre, University of
Cape Town, Cape Town, South Africa, 8 Department of Epidemiology and Biostatistics, University of
California, San Francisco School of Medicine, San Francisco, CA, United States of America, 9 Department of
Epidemiology and Department of Medicine, Columbia University Mailman School of Public Health, New York,
NY, United States of America, 10 Department of Biostatistics, University of Washington, Seattle, WA, United
States of America, 11 Gladstone Institutes, University of California, San Francisco, San Francisco, CA,
United States of America
☯ These authors contributed equally to this work.
* nbumpus1@jhmi.edu
Abstract
Tenofovir (TFV), a nucleotide reverse transcriptase inhibitor, requires two phosphorylation
steps to form a competitive inhibitor of HIV reverse transcriptase. Adenylate kinase 2 (AK2)
has been previously demonstrated to phosphorylate tenofovir to tenofovir-monophosphate,
while creatine kinase, muscle (CKM), pyruvate kinase, muscle (PKM) and pyruvate kinase,
liver and red blood cell (PKLR) each have been found to phosphorylate tenofovir-mono-
phosphate to the pharmacologically active tenofovir-diphosphate. In the present study,
genomic DNA isolated from dried blood spots collected from 505 participants from Bangkok,
Thailand; Cape Town, South Africa; and New York City, USA were examined for variants in
AK2, CKM, PKM, and PKLR using next-generation sequencing. The bioinformatics tools
SIFT and PolyPhen predicted that 19 of the 505 individuals (3.7% frequency) carried vari-
ants in at least one kinase that would result in a decrease or loss of enzymatic activity. To
functionally test these predictions, AK2 and AK2 variants were expressed in and purified
from E. coli, followed by investigation of their activities towards tenofovir. Interestingly, we
found that purified AK2 had the ability to phosphorylate tenofovir-monophosphate to tenofo-
vir-diphosphate in addition to phosphorylating tenofovir to tenofovir-monophosphate. Fur-
ther, four of the six AK2 variants predicted to result in a loss or decrease of enzyme function
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exhibited a30% decrease in activity towards tenofovir in our in vitro assays. Of note, an
AK2 K28R variant resulted in a 72% and 81% decrease in the formation of tenofovir-mono-
phosphate and tenofovir-diphosphate, respectively. These data suggest that there are natu-
rally occurring genetic variants that could potentially impact TFV activation.
Introduction
Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor that, when administered as the
prodrug tenofovir disoproxil fumarate (TDF), is used for the treatment and prevention of
human immunodeficiency virus (HIV) infection [1]. In fact, co-formulated emtricitabine/
tenofovir disoproxil fumarate is currently the only drug approved by the FDA for use in HIV
pre-exposure prophylaxis (PrEP) [2], although the CDC and WHO recommend TDF alone as
an alternate PrEP regimen. PrEP is a pharmacological strategy for preventing HIV infection,
the efficacy of which has been bolstered by several clinical trials [3] including the iPrEX study
comprised of 2,499 men who have sex with men (MSM) or transgender women (TGW) [4],
the Botswana TDF2 study comprised of 1,219 men and women [5], and the Partners PrEP
study, comprised of 4,747 serodiscordant couples [6]. The iPrEX study demonstrated a 92%
reduction in HIV incidence among MSM and TGW who had any detectable PrEP medications
in blood [4], and no participant became infected if drug levels indicated use of 4 or more tab-
lets per week [7]. In the Botswana TDF2 study, 78% of HIV-uninfected men and women were
protected against HIV when adjusted for adherence [5]. Finally, in the largest of these studies,
Partners PrEP, a 90% decrease in HIV infection among HIV-uninfected partners in compari-
son to placebo was observed [6].
In order to produce the active HIV reverse transcriptase inhibitor, TFV must be phos-
phorylated twice, first to tenofovir-monophosphate (TFV-MP) [8]. TFV-MP then is phosphor-
ylated to tenofovir-diphosphate (TFV-DP), which is the pharmacologically active form of
TFV. Our lab has investigated this phosphorylation pathway and demonstrated the compart-
ment specificity of the kinases involved in TFV activation [9]. Specifically, we found that ade-
nylate kinase 2 (AK2) phosphorylates TFV to TFV-MP in peripheral blood mononuclear cells
(PBMC), and in vaginal and colorectal tissue. Interestingly, while we observed phosphoryla-
tion of TFV-MP to TFV-DP by creatine kinase, muscle (CKM) in colorectal tissue, the kinases
pyruvate kinase, muscle (PKM) and pyruvate kinase, liver and red blood cell (PKLR) catalyzed
this step in PBMC and vaginal tissue [9]. Through this work, we proposed the possibility
that genetic variants of these kinases could impact the kinase function and therefore TFV
phosphorylation.
Adenylate kinases (AK) play a vital role in cellular energy metabolism and homeostasis.
These enzymes maintain adenine nucleotide ratios by catalyzing the reversible phosphotrans-
fer from ATP to AMP, resulting in two ADP molecules [10]. AK deficiency or mutations that
compromise AK activity, like the nucleotide kinase-dead mutant (AK2 K28E), can lead to con-
genital disorders such as reticular dysgenesis and disruptions in normal cellular function [11,
12]. Like AK, creatine kinases also play a role in cellular energy homeostasis, specifically in tis-
sue with high-energy demand such as striated muscles. Creatine kinases do this by utilizing
ATP to convert creatine (Cr) to phosphocreatine (PCr), which serves as an energy pool for
rapid regeneration of ATP [13]. Mutations in the CKM coding region compromise its activity.
A D54G variant of CKM was unable to properly fold, resulting in decreased activity as well
as its susceptibility to aggregation [14]. Pyruvate kinase catalyzes the rate-limiting step in
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glycolysis by converting phosphoenolpyruvate (PEP) to pyruvate and transferring the phos-
phate group to ADP, yielding one molecule of ATP [15]. Overexpression of PKs, specifically
PKM2, have been seen in cancer cells, while deficiency in PKs have been linked to hemolytic
anemias [15, 16]. Because it has been demonstrated that genetic mutations exist that can have
deleterious effects on the activities of these kinases toward their naturally occurring substrates,
we hypothesize that genetic variants of these kinases could also impact their ability to catalyze
the phosphorylation of TFV.
Thus, in the present study, we analyzed genomic DNA isolated from dried blood spots
(DBS) in 505 clinical trial participants across three geographic locations, namely Bangkok,
Thailand (n = 171), New York City, USA (n = 149), and Cape Town, South Africa (n = 185).
Of particular note, this study represents the first targeted resequencing analysis of the AK2,
CKM, PKM, and PKLR genes in subjects in Asia. We have also expressed and purified 12 vari-
ants of AK2 to demonstrate the impact of these genetic variants on TFV phosphorylation.
Taken together, this work establishes the concept that due to genetic variations, certain indi-
viduals may exhibit a decreased ability to activate TFV.
Materials and methods
Clinical study sites and sample collection
DBS were obtained from HIV-uninfected MSM or TGW and women who have sex with men
(WSM) (n = 505) enrolled in the HIV Prevention Trials Network study HPTN 067. The study
was conducted following local IRB approval at three clinical research sites (CRS): Emavudleni
CRS in Cape Town, South Africa; Silom Community Clinic CRS in Bangkok, Thailand; and
the Harlem Prevention Center CRS in New York, United States. Only subjects who provided
written consent to genetic testing were genotyped. Each participant contributed five DBS con-
taining approximately 50 μL of whole blood spotted onto WhatmanTM 903 Protein Saver
Cards. Information about participants enrolled and genotyped in this study is summarized in
Table 1.
Genomic DNA isolation from HPTN 067 DBS samples
Genomic DNA was isolated from two DBS from each individual using a QIAamp 96 DNA
Blood Kit (QIAGEN, Valencia, CA). DBS were punched out using a hole puncher and the
genomic DNA was extracted simultaneously from each of the two DBS (such that the extracted
genomic DNA from the two DBS was combined) following the supplementary protocol “Isola-
tion of genomic DNA from dried blood spots using the QIAamp 196 DNA Blood Kit–(EN)”
from QIAGEN. Purified DNA was eluted using 150 μL DEPC-treated, nuclease-free water
(Quality Biological, Inc., Gaithersburg, MD) and concentrated using a ZR-96 DNA Clean-up
Table 1. HPTN 067 participant enrollment location and gender information.
HPTN 067 study locations and participant demographics n = 505
Study site Reported gender n (% of n)
Bangkok, Thailand MSM, TGW 171 (34)
New York City, USA MSM, TGW 149 (30)
Cape Town, South Africa WSM 185 (36)
Study participants were enrolled across three geographic locations, with MSM and TGW enrolled in Bangkok
(n = 171) and New York City (n = 149) and WSM enrolled in Cape Town (n = 185).
https://doi.org/10.1371/journal.pone.0195764.t001
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KitTM (Zymo Research, Irvine, CA). The resulting concentrated and purified genomic DNA
was eluted in 12 μL DEPC-treated, nuclease-free water.
Next-generation sequencing target design, sample preparation, and
analysis
Sequencing of the kinases AK2, CKM, PKM and PKLR was executed in each gene’s exonic
regions using the Illumina TruSeq Custom Amplicon kit v1.5 (Illumina, San Diego, CA).
Probes for sequencing the combination of these kinases were designed using Illumina Design-
Studio software as previously described [9]. Genomic DNA isolated from clinical samples was
processed following the Illumina TruSeq Custom Amplicon Library Preparation Guide (Part
Number 15027983 Rev. C, August 2013). DNA concentration was measured using a Qubit1
3.0 Fluorimeter (Thermo Scientific, New York, NY). Fifty ng of DNA input were used per
DNA sample sequenced. The resulting prepared DNA library (6 μL) was diluted in 594 μL
HT1 buffer containing 1% PhiX sequencing control. Illumina VariantStudio software was
used to annotate and analyze variant read quality as previously described [9]. To predict the
consequences of the detected variants on kinase activity the in silico tools SIFT (sorts intoler-
ant from tolerant substitutions; J. Craig Venter Institute online tool) and PolyPhen (polymor-
phism phenotyping; Harvard University online tool) were used. A SIFT score< 0.05 is
commensurate with a prediction that the amino acid substitution is possibly deleterious
and> 0.05 indicates a tolerated amino acid substitution. A PolyPhen score > 0.908 is sugges-
tive of a probably damaging, 0.447–0.908 a possibly damaging, or < 0.447 a benign amino acid
substitution [17, 18].
Expression and purification of wild-type (WT) AK2
E. Coli BL21(DE3) cells (Agilent Technologies) were transformed with pET30a-AK2 plasmid
(AK2 was purchased from Origene), grown in Luria Broth (LB) medium containing 50 μg/mL
kanamycin at 37˚C to an OD600 of 0.8. Cells were induced with 1 mM isopropyl β-D-1-thioga-
lactopyranoside (IPTG) and grown for an additional 3 h at 37˚C. Cells were recovered by cen-
trifugation and resuspended in lysis buffer (50 mM HEPES pH 7.3, 150 mM KCl, 10 mM
MgCl2, 5% glycerol, 2 mM 2-mercaptoethanol, and 1x EDTA-free protease inhibitor cocktail
(Roche)). Cells were lysed by sonication and lysate was clarified by centrifugation (15,000 rpm,
45 min, at 4˚C). The resulting supernatant was applied to 1 mL of Superflow Co2+ resin
(HiTrap TALON, GE Healthcare), washed with 10 column volumes of lysis buffer, and eluted
using a gradient elution with lysis buffer supplemented with 500 mM imidazole. Following
purification, AK2 protein was dialyzed in storage buffer (20 mM HEPES pH 7.3, 150 mM KCl,
10 mM MgCl2, 5% glycerol, and 2 mM 2-mercaptoethanol) and stored at -80˚C.
Expression and purification of AK2 variants
Site directed mutagenesis was performed using wild-type pET30a-AK2 as a template. Amino
acid residues in AK2 were mutated using a modified quick-change procedure [19] to produce
each of the 12 previously unreported variants of this kinase that were detected in this study
(A8V, V19G, K28R, A52T, A55V, E59K, K62E, E77K, E155K, T194I, I206F, I206V). These
experiments were performed using a QuikChange Lightning Kit from Agilent Technologies.
All mutations were confirmed by DNA sequencing (The Synthesis and Sequencing Facility,
John Hopkins University). Expression and purification of these variants were carried out in
the same way as wild-type AK2, as described in the prior paragraph.
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AK2 activity assay, sample preparation, and detection of TFV-MP and
TFV-DP formation
In a reaction volume of 200 μL, 500 nM recombinant proteins (wild-type AK2 or AK2 vari-
ants), 1 mM TFV, and 1 mM ATP were incubated in assay buffer (20 mM HEPES pH 7.3,
100 mM KCl, 10 mM MgCl2, 2 mM DTT) at 37˚C for 2.5 h. A saturating concentration of
TFV was used to ensure that substrate depletion would not underlie any differences observed
in the formation of phosphates in these activity assays. A 100 μL aliquot was taken from the
reaction, quenched in 1 mL methanol/formic acid (0.1%) solution, and incubated on ice for 10
min. Samples were then centrifuged for 10 min at 10,000 g and supernatant was dried under
vacuum. Analysis of TFV, TFV-MP, and TFV-DP was done using a Dionex Ultimate 3000
uHPLC system coupled to a TSQ Vantage Triple Stage Quadrupole mass spectrometer (Ther-
moFisher Scientific). Separation of these analytes was done using a HALO C18, 100x2.1 mm,
2.7 μm particle size column (Advanced Materials Technology) at a flow rate of 0.45 mL/min.
Mobile phase A (MPA) was 5 mM N,N-Dimethylhexylamine (DMHA) in water, pH 7.0, and
B (MPB) was 5 mM DMHA in acetonitrile/water (50:50, v/v). A gradient program was used
and is as follows: 0–53% MPB from 0–6 min, 53–100% MPB from 6–6.5 min, 100% MPB from
6.5–10 min, 100–0% MPB from 10–10.5 min, and 0% MPB from 10.5–20 min. Samples were
reconstituted with 30 μL MPA, and injection volume was 1 μL. The ESI source of the TSQ
Vantage mass spectrometer was operated in the positive ion mode and fragment ions were
detected using the following transitions: m/z 288!176, 368!270, 488!270 for TFV, TFV-
MP, and TFV-DP, respectively. Data were acquired and processed using Xcalibur (Thermo-
Fisher Scientific).
Statistical analysis
Differences of TFV-MP and TFV-DP formation between wild-type AK2 and AK2 variants
were compared using a two-tailed unpaired t test. This was performed using GraphPad Prism
(San Diego, CA), and significance was set as follows: , p0.05; , p0.01; , p0.001.
Results
Analysis of individuals carrying genetic variants in tenofovir-activating
kinases AK2,CKM, PKM, and PKLR
Variant distribution among Bangkok study participants is demonstrated using a Venn dia-
gram in Fig 1. At the Bangkok study site, 29 of the 171 participants sequenced (17%) for these
kinases carried single nucleotide variants (SNVs) or deletions that were predicted to result in a
mutation at the amino acid level. Of these 29 participants from the Bangkok study site, 26 indi-
viduals exhibited variants for a singular nucleotide kinase. Moreover, one individual had a var-
iant detectable for only AK2, nine individuals had variants detectable for only CKM, eight
individuals had variants detectable for only PKM, and eight individuals had variants detectable
for only PKLR. Of the remaining three participants, one carried variants detectable in AK2 and
PKM and two had genetic variants in both PKM and PKLR.
At the New York City study site, 35 of the 149 participants sequenced (23%) were observed
to carry SNVs or deletions predicted to result in a mutation at the amino acid level. The
observed variant distribution among New York City study participants is depicted using a
Venn diagram in Fig 1. Of the 35 participants from the New York City study site detected to
carry a genetic variant, 27 exhibited variants for only one of the kinases sequenced. Six individ-
uals carried variants for AK2 alone, seven individuals for CKM alone, six individuals for PKM
alone, and eight individuals carried variants for PKLR alone. Further, of these 35 participants,
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eight carried genetic variants in more than one kinase. One individual had detectable variants
in AK2, PKM, and PKLR, two individuals were observed to have detectable variants in AK2
and PKLR, two individuals were observed to have detectable variants in CKM and PKM and
three individuals were observed to carry variants in PKM and PKLR.
Variant distribution among Cape Town study participants is shown using a Venn diagram
in Fig 1. Thirty of the 185 participants (16%, 30/185) enrolled at this study site were observed
to have SNVs or deletions predicted to result in a mutation at the amino acid level. Twenty-
two of the 30 individuals carrying variants in Cape Town exhibited single nucleotide variants
for only one of the kinases sequenced. Of these 22 individuals, two displayed variants in the
kinase AK2 alone, seven in the kinase CKM alone, five in the kinase PKM alone, and eight in
the kinase PKLR alone. In contrast to exhibiting variants in only one kinase, eight participants
carried genetic variants in more than one kinase. Two individuals were observed to have
detectable variants in AK2 and PKM. One individual was observed to have detectable variants
in both AK2 and CKM. Seven individuals were observed to have detectable variants in only
CKM, while two were observed to have detectable variants in CKM and PKM and two to have
detectable variants in CKM and PKLR. Five were observed to have detectable variants in PKM.
Eight individuals were observed to have detectable variants in PKLR. One individual was
observed to carry detectable variants in PKM and PKLR.
AK2 genetic variants detected across three geographic locations
Our laboratory has previously demonstrated AK2 phosphorylation of TFV to TFV-MP in
PBMC, vaginal tissue, and colon tissue [9]. This previous study identified 12 heterozygous
missense variants that had never before been reported; however, none of the AK2 variants
identified through this previous work were found in our current study. In the 505 participants
sequenced in this study, we observed 17 single nucleotide variations (SNVs) predicted to result
in a mutation of the amino acid sequence for the DNA reference sequence corresponding to
AK2 (NM_001625.3). These specific variants were detected across 16 individuals. The de-
scribed variants, which include both previously reported and novel variants, are detailed in
Table A in S1 File. All 16 individuals were observed to be heterozygous for the variants
detected. Further, of the 16 individuals observed to carry at least one SNV, two individuals
Fig 1. Distribution of individuals enrolled at the Bangkok, Cape Town, and New York City study sites carrying genetic variants in TFV-activating kinases.
Each rectangle is representative of a TFV-activating kinase that was sequenced: AK2 in blue, CKM in pink, PKM in orange and PKLR in green. Numerical values
indicate the number of individuals detected to carry a single nucleotide variation or deletion. Overlapping regions of each rectangle indicate the number of
individuals with genetic variants in more than one kinase.
https://doi.org/10.1371/journal.pone.0195764.g001
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were from the Bangkok study site, five individuals were of the Cape Town study site, and nine
individuals were of the New York City study site. Among the individuals carrying at least one
SNV, one individual at the Cape Town study site was observed to be carrying two variants
while two individuals at the New York City study site were observed to be carrying two vari-
ants. Of the 17 AK2 genetic variants observed, 13 of these variants, which were detected across
11 participants, were previously unreported (Table 2). Twelve of the 13-abovementioned vari-
ants were missense substitutions. Of the 505 individuals sequenced for AK2 missense variants,
one individual in New York City was observed to have the previously unreported variant at the
coding DNA position c.664G>A. Applying in silico functional prediction tools to the variant
c.664G>A, it is predicted to be “deleterious” and “probably damaging”. In silico tools SIFT
and PolyPhen were used to predict the functional consequences of these variants as previously
described [9]. Four variants contained in the Single Nucleotide Polymorphism database
(dbSNP), were detected and are listed as follows: rs143825456 (NM_001625.3:c.631G>A) was
detected in two individuals, with one individual located in Bangkok and the other in Cape
Town; rs148421308 (NM_001625.3:c.460G>A) was detected in one individual in New York
City; rs61750965 (NM_001625.3:c.386G>A) was detected in one individual in New York City;
and rs12116440 (NM_001625.3:c.625G>A) was detected in one individual in New York City.

















Bangkok T>C 699 616 206 I>V tolerated
(0.38)
benign(0.063)
Cape Town G>A 106 23 8 A>V tolerated
(0.27)
benign(0.002)
Cape Town T>C 166 83 28 K>R deleterious(0) possibly_damaging
(0.693)
Cape Town G>A 247 164 55 A>V deleterious(0) possibly_damaging
(0.774)
Cape Town C>T 258 175 59 E>K tolerated
(0.29)
benign(0.01)




New York City A>C 139 56 19 V>G deleterious(0) possibly_damaging
(0.882)




New York City T>C 267 184 62 K>E tolerated
(0.59)
benign(0.134)
New York City C>T 546 463 155 E>K tolerated
(0.59)
benign(0.187)
New York City G>A 664 581 194 T>I deleterious(0) probably_damaging
(0.997)
New York City T>C 699 616 206 I>V tolerated
(0.38)
benign(0.063)
New York City T>A 699 616 206 I>F deleterious
(0.03)
benign(0.288)
Twelve previously unreported genetic missense variants were detected in 11 individuals out of 505 individuals sequenced for the coding DNA reference sequence
NM_001625.3. All individuals that had detectable variants were heterozygous for those variants. One individual from Cape Town had two detectable missense variants
and one individual from New York City had two detectable missense variants. Across the three geographic locations where individuals were sequenced for AK2, one
AK2 variant was found in both Bangkok and New York City but not in Cape Town.
https://doi.org/10.1371/journal.pone.0195764.t002
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Detection of CKM sequence variants
For the DNA reference sequence corresponding to CKM (NM_001824.4), 34 total variants
comprised of SNVs and deletions that are predicted to be reflected in the amino acid sequence
were detected across 30 individuals. The total observed variants, including previously reported
and previously unreported variants, are listed in Table B in S1 File. Twenty-nine individuals
were observed to be heterozygous for all the variants detected, while one individual in New
York City was observed to be homozygous. Of the 30 individuals observed to have detectable
SNVs or deletions, nine individuals were located at the Bangkok study site, 12 individuals were
located at the Cape Town study site, and nine individuals were located at the New York City
study site. We observed two clinical trial participants exhibiting more than one variant for this
kinase. One individual at the Bangkok study site was observed to carry two different variants,
and one individual at the Cape Town study site was observed to carry two variants. Twenty-six
previously unreported single nucleotide variants or base deletions were detected across 24
individuals (Table 3). Of the 505 individuals sequenced for CKM missense variants, nine indi-
viduals were observed to have a predicted “deleterious” and “probably damaging” variant,
yielding a frequency of 1.8%. In silico tools SIFT and PolyPhen were used to predict the func-
tional consequences of these variants. Five reported variants, found in the dbSNP, were de-
tected: rs149354459 (NM_001824.4:c.752G>A) in one individual from Bangkok, rs17875625
(NM_001824.4:c.728G>T) in one individual from Bangkok; rs201048164 (NM_001824.4:
c.163G>A) in one individual from Cape Town; rs17850202 (NM_001824.4:c.673T>C) in one
individual from New York City, and rs11559024 (NM_001824.4:c.248A>G) in one individual
from New York City. Of note, the individual carrying the rs11559024 variant was homozygous
and, using both of the informatics tools employed this variant, was predicted to result in a
decrease or loss of kinase activity.
PKM genetic variants
For the DNA reference sequence corresponding to PKM (NM_001206796.1), 39 total variants
comprised of SNVs and deletions that are predicted to be reflected in the amino acid sequence
were detected across 33 individuals. The 39 observed variants, which include both previously
reported and previously unreported variants, are listed in Table C in S1 File. All 33 individuals
carrying variants in PKM were observed to be heterozygous for all the described PKM variants.
Of the 33 individuals observed to have detectable SNVs or deletions, 11 individuals were located
at the Bangkok study site, 10 individuals were located at the Cape Town study site, and 12 indi-
viduals were located at the New York City study site. One individual at the Cape Town study site
was observed to carry two variants. Two individuals at the New York City study site were
observed to carry three variants. Thirty-three previously unreported single nucleotide variations
or base deletions were detected across 29 individuals (Table 4). Three reported variants, found in
the dbSNP, were detected and are listed as follows: rs141732747 (NM_001206796.1:c.827C>A)
was detected in one individual from New York City; rs185164430 (NM_001206796.1:c.1695C>
G) was detected in one individual from New York City and rs778625515 (NM_001206797.1:
c.132C>G) was detected in one individual from Cape Town. For the variants detected in PKM,
functional predictions at the protein level were unavailable because the in silico tools, SIFT and
Polyphen, were unable to achieve sufficient sequence diversity information in the multiple align-
ments necessary for prediction.
PKLR sequence variants
For the DNA reference sequence corresponding to PKLR (NP_000289.1), 39 total variants
comprised of SNVs and deletions that are predicted to be reflected in the amino acid sequence
Tenofovir activating kinase variants: HPTN 067
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Bangkok C>T 303 128 43 R>Q tolerated
(0.07)
benign(0.288)
Bangkok T>C 693 518 173 Y>C deleterious(0) probably_damaging
(0.991)




Bangkok T> C 713 538 180 T>A deleterious(0) benign(0.086)
Bangkok C> A 977 802 268 G>C deleterious(0) possibly_damaging
(0.822)
Bangkok T> G 1262 1087 363 M>L tolerated
(0.35)
benign(0.08)
Cape Town G> C 451 276 92 I>M deleterious(0) probably_damaging
(0.951)
Cape Town G> A 569 394 132 R>C deleterious(0) probably_damaging
(0.999)




Cape Town C> T 638 463 155 E>K deleterious(0) benign(0.177)








Cape Town C> A 991 816 272 M>I tolerated
(0.05)
benign(0.142)
Cape Town T> A 995 820 274 N>Y deleterious(0) probably_damaging
(0.91)
Cape Town C> A 1013 838 280 V>L tolerated
(0.18)
benign(0.159)
Cape Town T> A 1032 857 286 N>I deleterious(0) probably_damaging(1)
Cape Town C> G 1064 889 297 V>L tolerated
(0.21)
benign(0.299)




New York City C> A 392 217 73 G>C deleterious(0) probably_damaging
(0.997)
New York City T> A 435 260 87 E>V deleterious
(0.02)
benign(0.402)
New York City T> A 482 307 103 T>S tolerated
(0.62)
benign(0.001)
New York City T> C 720 545 182 K>R tolerated
(0.11)
benign(0.017)
New York City A> T 806 631 211 W>R deleterious(0) probably_damaging
(0.994)
New York City T> G 837 662 221 D>A tolerated
(0.08)
benign(0.148)
New York City A> G 924 749 250 F>S deleterious(0) probably_damaging(1)
New York City C> T 1172 997 333 V>I tolerated(0.3) benign(0.085)
Twenty-six previously unreported genetic missense variants were detected in 24 individuals out of 505 individuals sequenced for the coding DNA reference sequence
NM_001824.4. All individuals that had detectable missense variants were heterozygous for those variants. One participant from Bangkok had two missense variants and
one participant from Cape Town had two missense variants. Across the three geographic locations evaluated for genetic variants for this kinase, no CKM variants were
found in more than one geographic region.
https://doi.org/10.1371/journal.pone.0195764.t003
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were detected across 35 individuals. These observed variants are listed in Table D in S1 File.
Thirty-four individuals were determined to be heterozygous for the variants detected, with
one individual identified as homozygous for one variant. Of the 34 individuals observed to
have detectable SNVs or deletions, 10 individuals were located at the Bangkok study site, 11
individuals were located at the Cape Town study site, and 14 individuals were located at the
New York City study site. Two individuals at the Cape Town study site were observed to be
carrying two variants compared to four individuals at the New York City study site that carried
two variants. Thirty-one previously unreported SNV or base deletions were detected across 26
individuals (Table 5). One individual from Cape Town was homozygous for the variant

















Bangkok A>G 766 367 123 C>R N/A N/A
Bangkok T>C 904 505 169 T>A N/A N/A
Bangkok G>A 1007 608 203 T>I N/A N/A
Bangkok T>C 1058 659 220 N>S N/A N/A
Bangkok C>G 1399 1000 334 E>Q N/A N/A
Bangkok C>T 1502 1103 368 R>H N/A N/A
Bangkok G>A 1667 1268 423 A>V N/A N/A
Bangkok C>T 1752 1353 451 M>I N/A N/A
Bangkok T>C 1837 1438 480 T>A N/A N/A
Bangkok A>G 2065 1666 556 W>R N/A N/A
Cape Town G>A 437 38 13 T>M N/A N/A
Cape Town G>C 617 218 73 A>G N/A N/A
Cape Town C>T 688 289 97 A>T N/A N/A
Cape Town A>T 850 451 151 S>T N/A N/A
Cape Town T>C 1027 628 210 K>E N/A N/A
Cape Town T>C 1412 1013 338 N>S N/A N/A
Cape Town T>C 1762 1363 455 I>V N/A N/A
Cape Town G>A 1792 1393 465 H>Y N/A N/A
Cape Town C>T 2122 1723 575 G>S N/A N/A
Cape Town G>T 2177 1778 593 S>Y N/A N/A
New York City G>A 430 31 11 L>F N/A N/A
New York City C>T 1345 946 316 A>T N/A N/A
New York City T>C 1475 1076 359 E>G N/A N/A
New York City T>A 1492 1093 365 M>L N/A N/A
New York City T>C 1618 1219 407 S>G N/A N/A
New York City C>T 1655 1256 419 G>D N/A N/A
New York City T>A 1712 1313 438 E>V N/A N/A
New York City C>A 1741 1342 448 A>S N/A N/A
New York City A>T 1844 1445 482 L>H N/A N/A
New York City C>T 1849 1450 484 E>K N/A N/A
New York City A>G 1979 1580 527 V>A N/A N/A
New York City C>T 2047 1648 550 D>N N/A N/A
Thirty-three previously unreported genetic missense variants were detected in 29 individuals out of 505 individuals sequenced for the coding DNA reference sequence
NM_001206796.1. All individuals that had detectable variants were heterozygous for those variants. Across the three geographic locations evaluated for genetic variants
for this kinase, no PKM variants were found in more than one geographic region. Using in silico tools PolyPhen and SIFT, no functional predictions were available for
PKM. Thus, not applicable (N/A) is indicated in the table.
https://doi.org/10.1371/journal.pone.0195764.t004
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Bangkok G>A 89 50 17 S>F deleterious(0) benign(0)
Bangkok A>T 106 67 23 L>I tolerated
(0.06)
benign(0.024)
Bangkok C>T 161 122 41 R>Q deleterious
(0.01)
benign(0.175)




Bangkok G>C 368 329 110 A>G deleterious(0) possibly_damaging
(0.656)




Bangkok A>G 1334 1295 432 V>A deleterious(0) benign(0.062)
Bangkok T>C 1652 1613 538 E>G tolerated
(0.11)
benign(0.024)
Cape Town C>T 375 336 112 M>I deleterious
(0.01)
probably_damaging(1)
Cape Town C>A 578 539 180 G>V deleterious(0) probably_damaging
(0.996)
Cape Town G>T 947 908 303 P>Q deleterious
(0.05)
benign(0.13)








Cape Town A>T 1091 1052 351 L>Q deleterious(0) probably_damaging
(0.992)
Cape Town G>A 1313 1274 425 A>V deleterious
(0.01)
benign(0.111)
Cape Town C>T 1343 1304 435 R>Q tolerated
(0.63)
benign(0.01)
Cape Town T>A 1465 1426 476 T>S tolerated
(0.23)
benign(0.002)




New York City G>C 197 158 53 T>S tolerated
(0.47)
benign(0.008)
New York City G>T 368 329 110 A>D deleterious(0) possibly_damaging(0.9)
New York City A>G 460 421 141 F>L tolerated
(0.45)
benign(0.082)
New York City G>A 473 434 145 P>L tolerated(0.1) possibly_damaging
(0.653)
New York City A>T 524 485 162 I>N deleterious(0) probably_damaging
(0.999)
New York City G>A 530 491 164 T>I deleterious
(0.01)
probably_damaging(1)
New York City A>G 580 541 181 S>P tolerated
(0.26)
benign(0.315)
New York City A>T 866 827 276 V>E deleterious(0) probably_damaging
(0.986)
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G180V. All other participants that showed detected missense variants were heterozygous
for the variants. One individual from Cape Town carried two missense variants and four
individuals from New York City had two missense variants. Across the three geographic
locations evaluated for genetic variants in this kinase, no PKLR variants were found in more
than one geographic region; in addition, only two of the same variants were detected in more
than one individual. Of the 505 individuals sequenced for PKLR missense variants, nine indi-
viduals were observed to have at least one predicted “deleterious” and “probably damaging”
variant, yielding a frequency of 1.8%. In silico tools SIFT and PolyPhen were used to predict
the functional consequences of these variants. Six reported variants, found in the dbSNP,
were detected and are listed as follows: rs147689373 (NM_000298.5:c.829G>A) was found
in two individuals from New York City; rs116100695 (NM_000298.5:c.1456C>T) was found
in one individual from New York City and one individual from Cape Town; rs189360283
(NM_000298.5:c.1345C>T) was found in one individual from Cape Town; rs201979697
(NM_000298.5:c.907C>T) was found in one individual from Cape Town; rs201406712
(NM_000298.5:c.1435C>T) was found in one individual from New York City and
rs150077703 (NM_000298.5:c.92C>A) was found in one individual from Bangkok.
In vitro phosphorylation of tenofovir and tenofovir-monophosphate by
AK2 and AK2 variants that were detected in study participants
Since AK2 plays a critical role in TFV activation through carrying out the first phosphorylation
step that results in the formation of TFV-MP, we used AK2 activity assays as a model system
for testing the predictions regarding the impact of genetic variants on activity towards TFV.
AK2, as well as the 12 variants that were identified in study participants, were expressed and
purified in E. coli followed by the performance of assays to measure the ability of these en-
zymes to phosphorylate TFV. To do this, we established an AK2 activity assay for TFV as well
as an uHPLC-MS/MS that enabled the direct detection of TFV metabolites. We found that
AK2 not only phosphorylated TFV to TFV-MP, but further catalyzed the phosphorylation of
TFV-MP to TFV-DP (Fig 2). In addition, several of the variants exhibited differential activity
towards TFV as compared to the wild-type enzyme. Of the 12 variants we tested, V19G, K28R,
A55V, K62E, and T194I variants were found to be functionally affected, leading to statistically
significant decreases in the formation of TFV-MP to 67.4 ± 8.8%, 28.0 ± 2.8%, 70.0 ± 5.6%,
70.1 ± 3.9%, and 37.5 ± 4.0%, respectively, of that formed by the wild-type enzyme. Of note,
the K28R variant also exhibited a marked decrease in the formation of TFV-DP to 18.7 ± 3.2%

























New York City A>G 1520 1481 494 I>T deleterious(0) probably_damaging
(0.985)




Thirty-one previously unreported genetic missense variants were detected in 26 individuals out of 505 individuals sequenced for the coding DNA reference sequence
NP_000289.1.
https://doi.org/10.1371/journal.pone.0195764.t005
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decreased kinase activity toward TFV in our in vitro assays, 4 had been predicted using the
SIFT and PolyPhen bioinformatics tools to have decreased activity compared to wild-type.
Discussion
This study identified 103 previously unreported genetic variants of the kinases AK2, CKM,
PKM, and PKLR in 505 clinical trial participants located in Thailand, Cape Town, and the
United States. Using the SIFT and PolyPhen bioinformatics tools it was predicted that 19 of
the 505 individuals carried variants that would result in a decrease or loss of enzymatic activity.
The breakdown for this was one individual with an AK2 variant predicted to be deleterious or
possibly damaging and 9 individuals each with CKM or PKLR variants predicted to negatively
impact kinase activity. Each variant in this study was unique, in that it was only detected in
one individual. While next-generation sequencing has been applied to genomic DNA ex-
tracted from dried blood spots in prior studies [20–23], interrogating this extracted DNA for
sequence variants in these kinases has not yet been carried out. To increase confidence in the
variants identified, our analyses conformed to the American College of Medical Genetics and
Genomics clinical laboratory standards for next-generation sequencing [24]. To compare fre-
quencies in this study of previously reported genetic variants, data from the 1000 Genomes
Project [25] and the Exome Aggregation Consortium (ExAC) [26], which includes over 60,000
Fig 2. Naturally occurring genetic variants of AK2 and the resulting impact on TFV phosphorylation. Wild-type
(WT) AK2 and variants were expressed in and purified from E. coli in order to evaluate their effects on TFV
phosphorylation in vitro. Proteins were incubated with 1 mM TFV in assay buffer for 2.5 h before reaction was
quenched. A saturating concentration of TFV was used in order to ensure that substrate depletion would not play a
causal role in differences observed in the formation of phosphates in these activity assays. TFV-MP and TFV-DP were
detected by uHPLC-MS/MS where signal to noise ratio was used to establish the corresponding bar graph. Error bars
represent standard deviation; n = 3. A two-tailed unpaired t test and significance was set as follows: , p0.05; ,
p0.01; , p0.001.
https://doi.org/10.1371/journal.pone.0195764.g002
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genotyped, unrelated individuals, was used because of the population and, in the case of the
1000 Genomes Project, location information these datasets provide.
In comparison to a previous analysis from our laboratory that sequenced 142 women from
the geographic regions Durban, South Africa, Kampala, Uganda, and four locations within
the United States [9], we detected one overlapping variant for the four kinases sequenced. Of
note, in the abovementioned study, there was no overlap in the variants that were detected
among the participants. With this in mind it is interesting that PKM SNP rs778625515
(NM_001206796.1:c.354C>G) was detected in one clinical trial participant at the USA study
site from our previous analysis and shared with one participant at the Cape Town study site in
our current study. At the protein level, this PKM variant is predicted to result in a mutation
from asparagine to lysine at amino acid residue 118 (N118K). This mutation is located adja-
cent to a beta strand comprised of amino acids 119 to 121 [27]. Because of its location two
amino acids away from a reported ATP binding site, it is possible binding of this substrate will
be disrupted, affecting kinase function; however, as noted above, the gene encoding PKM cur-
rently has no functional prediction of this variant using in silico tools PolyPhen or SIFT. Func-
tional predictions of the variants detected in PKM at the protein level were unavailable because
the in silico tools used for prediction, SIFT and PolyPhen, were not supplied with sufficient
sequence diversity required for the performed multiple sequence alignments necessary for the
algorithms used in these predictions.
In the present study, we detected the SNV rs147689373 (NM_000298.5:c.829G>A) of
PKLR in two individuals in New York City, yielding a 1.3% (2/149) frequency within New
York City and a 0.40% (2/505) frequency in our study. Of note, this variant was detected in
one participant in South Africa in our previous study [9]. In the 1000 Genomes Project, the
overall frequency for this variant was 0.26%. The only location in the USA included in the
1000 Genomes Project reporting frequency was 0.78% in the Mexican Ancestry from Los
Angeles USA. The frequency of this variant in the 1000 Genomes Project from other locations
was 2.1% in African Caribbeans in Barbados, 1.0% Esan in Nigeria, 1.52% Luhya in Webuya
Kenya, 1.18% Mende in Sierra Leone, and 0.46% Yoruba in Ibadan, Nigeria. At the protein
level, this variant results in a mutation at the 277th amino acid with a substitution from glu-
tamic acid to lysine. Other previously reported variants around this region of the protein have
been associated with pyruvate kinase deficiency [28].
Of the previously reported variants detected in our study, the SNP in CKM rs11559024
(NM_001824.4:c.248A>G) was the only variant reported at an overall frequency greater than
1% across the ExAC database. This variant was detected in one individual from New York
City, exhibiting a 0.20% (1/505) overall frequency across the three geographic locations in this
study and a 0.67% (1/149) frequency in the New York City population we examined. Across
data listed in the ExAC database, a total frequency of 1.1% throughout all the subpopulations
included in the database is reported. All subpopulations exhibited frequencies of this variant,
with Finnish European at 1.94%, non-Finnish European at 1.51%, South Asian at 0.58%,
Latino at 0.36%, African at 0.36%, and the East Asian population exhibiting 0.01% frequency.
Consulting the 1000 Genomes Project, this variant is reported at the following frequencies in
the following sites located in the USA: 0.25% in Utah Residents with Northern and Western
European Ancestry, 0.49% in Gujarati Indians from Houston, Texas population, and 0.78% in
individuals reporting Mexican Ancestry from Los Angeles USA. Populations from the 1000
Genomes Project outside the United States showed frequencies at 0.58% in Bengali from Ban-
gladesh, 0.49% in Han Chinese in Beijing, 0.53% in Colombians from Medellin, Colombia,
1.52% in Finnish in Finland, 1.65% in British in England and Scotland, 1.04% in Punjabi from
Lahore, Pakistan, and 0.48% in Puerto Ricans from Puerto Rico. Overall, in the populations
included in the 1000 Genomes Project combined, the frequency of this variant was 0.38%—a
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higher overall frequency than that observed in our study. The resulting protein from this variant
would exhibit a residue change at the 83rd amino acid of the protein, resulting in the mutation
of a glutamic acid to glycine. In silico functional prediction tools, predict that this substitution
would be “deleterious” using the SIFT algorithm and “possibly damaging” using PolyPhen.
To test these in silico predictions, AK2 and the 12 AK2 genetic variants that were identified
in this study were generated in vitro to examine their activity towards TFV. To confirm that
our assay was viable, we first looked at the activity of WT-AK2, previously suggested to initiate
the first phosphorylation step of TFV [9], towards TFV. We found that AK2 indeed phosphor-
ylated TFV to TFV-MP; however, interestingly we also found that AK2 could catalyze the
phosphorylation of TFV-MP to TFV-DP. Utilizing the same assay, we investigated the 12 vari-
ants and their effect on activity towards TFV. The V19G, K28R, A55V, K62E, and T194I vari-
ants were found to negatively impact kinase activity, leading to a decrease in the formation of
TFV-MP compared to wild-type;however, only K28R and T194I exhibited a marked decrease
in TFV phosphorylation in our functional assays. Future studies using a range of TFV concen-
trations in these assays are required to gain a more complete understanding of the impact of
AK2 genetic variants on phosphorylation since the use of a single TFV concentration, as was
done in the present study, may not fully reveal the effects of these AK2 variants on activity.
Interestingly, in line with our finding that AK2 can also phosphorylate TFV-MP to TFV-DP,
the K28R exhibited a decrease in the formation of TFV-DP compared to wild-type. Further,
since the participants in our study were all heterozygous for these variants, it is difficult to pre-
dict from our data what the clinical impact might be; however, given the possibility that there
are individuals homozygous for these variants our functional data shed light on the potential for
differences in TFV activation based on genotype. To this end, the K28R variant is of particular
interest since clinically, it has been demonstrated that a genetic mutation at this same residue is
associated with a loss of AK2 activity (AK2 K28E variant) that results in reticular dysgenesis
and disruptions in normal cellular function [11, 12]. The lysine at position 28 is reported to be
in the middle of the ATP binding domain of AK2 [27], the region that plays a role in catalyzing
the transfer of a phosphate group from an ATP molecule and mutations within the ATP bind-
ing domain could functionally affect this activity. The lysine to arginine mutation may be dis-
rupting the source of phosphate to transfer onto TFV, which would explain the decrease in both
TFV-MP and TFV-DP formation. The decrease in TFV-MP formation seen in the other vari-
ants suggests that these amino acid residues may be important in the binding of TFV. However,
since we demonstrated that AK2 also has activity towards TFV-MP that results in the formation
of TFV-DP, we cannot rule out the possibility that the decrease in TFV-MP formation is due to
increased TFV-DP formation. To elucidate this, future studies to investigate the enzyme kinetics
of the phosphorylation of TFV and TFV-MP are required, in addition to biophysical studies to
probe the binding of TFV to the AK2 variants.
Our observation of little overlap between individuals in the variants identified suggests that
while genetic differences in these kinases exist, the variants are of low frequency. This makes
the probability of detecting mutations that might affect TFV activation in a given population
difficult to ascertain. Further, since several enzymes are involved in the cascade of TFV activa-
tion, the actual clinical impact of a variant of one enzyme is difficult to predict and it is likely
that for substantial loss in TFV activation to occur an individual would need to carry variants
of more than one enzyme. In addition, due to the low frequency of the genetic variants
detected within the HPTN 067 study participants, correlations between TFV and TFV-DP lev-
els and our data were not possible. Further, adherence is an issue that impacts HIV PrEP stud-
ies and this makes it difficult to elucidate the impact of genotype on study drug levels when the
number of individuals carrying genetic variants is low. Thus, in order to perform a powerful
analysis, a future study is required in which directly observed therapy is employed and
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participants are enrolled based on genotype, similar to a previous study that we have per-
formed investigating the impact of genetics on the metabolism of the anti-HIV drug maraviroc
[29]. Importantly, our results demonstrate that the extraction of genomic DNA from dried
blood spots can facilitate the detection of tenofovir-activating kinases genetic variants, indicat-
ing that this low-cost, limited sample method can be used in large-scale clinical trials for teno-
fovir pharmacogenetics applications. In addition, these data offer new, previously unreported
variants across the AK2, CKM, PKM, and PKLR genes, which encode the kinases that play a
role in tenofovir activation. Of note, several of these kinases were predicted to result in a loss
or a decrease in the function of the protein and our functional assays have provided verifica-
tion that naturally occurring genetic variants can have an effect on TFV phosphorylation.
Taken together, this work suggests that divergence in drug concentrations observed among
PrEP users could be due to genetic variation in TFV activation rather than adherence alone.
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